Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

Rajagopal V. Sekhar; Farook Jahoor; Henry J. Pownall; Christie M. Ballantyne; Ashok Balasubramanyam

doi:10.1007/s11883-004-0029-2

Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

Rajagopal V. Sekhar, Farook Jahoor, Henry J. Pownall, Christie M. Ballantyne, Ashok Balasubramanyam

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease.

Original language	English (US)
Pages (from-to)	173-179
Number of pages	7
Journal	Current Atherosclerosis Reports
Volume	6
Issue number	3
DOIs	https://doi.org/10.1007/s11883-004-0029-2
State	Published - May 2004

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11883-004-0029-2

Cite this

@article{074ca42b8e884cec85fb63e4653a9756,

title = "Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy",

abstract = "The emergence of a new metabolic syndrome in patients with HIV infection, termed {"}HIV-associated dyslipidemic lipodystrophy{"} (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease.",

author = "Sekhar, {Rajagopal V.} and Farook Jahoor and Pownall, {Henry J.} and Ballantyne, {Christie M.} and Ashok Balasubramanyam",

note = "Funding Information: This work was supported by NIH grants DK-59537 and HL-73696 to A.B., and HL-30914 and HL-56865 to H.P.",

year = "2004",

month = may,

doi = "10.1007/s11883-004-0029-2",

language = "English (US)",

volume = "6",

pages = "173--179",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Current Medicine Group",

number = "3",

}

TY - JOUR

T1 - Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

AU - Sekhar, Rajagopal V.

AU - Jahoor, Farook

AU - Pownall, Henry J.

AU - Ballantyne, Christie M.

AU - Balasubramanyam, Ashok

N1 - Funding Information: This work was supported by NIH grants DK-59537 and HL-73696 to A.B., and HL-30914 and HL-56865 to H.P.

PY - 2004/5

Y1 - 2004/5

N2 - The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease.

AB - The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=3142628401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142628401&partnerID=8YFLogxK

U2 - 10.1007/s11883-004-0029-2

DO - 10.1007/s11883-004-0029-2

M3 - Review article

C2 - 15068741

AN - SCOPUS:3142628401

SN - 1523-3804

VL - 6

SP - 173

EP - 179

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 3

ER -

Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this